Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:13:02.425Z.
Calculation as of: 2026-10-06T16:13:02.425Z.
Quote observation: 2026-10-06T16:06:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 75157c8a62e3fe86a7e5d9b3960d4dd2a79ae28b02be5cac6a633fb547f90e56
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$155.86M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$158.63M
EV/EBITDA Ratio
N/A
TTM Avg
22.86x
3Y Avg
22.86x
5Y Avg
22.86x
Market Cap
$154.07M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$164.54M
EV/EBITDA Ratio
N/A
TTM Avg
8.39x
3Y Avg
66.32x
5Y Avg
66.32x
Market Cap
$152.74M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$166.35M
EV/EBITDA Ratio
10.47x
TTM Avg
86.42x
3Y Avg
168.75x
5Y Avg
173.55x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $155.86M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $158.63M | N/A | 22.86x | 22.86x | 22.86x |
| Inogen, Inc. (INGN)vs › | $158.32M | N/A | 29.09x | 58.55x | 59.27x |
| PepGen Inc. (PEPG)vs › | $162.20M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.07M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | N/A | 8.39x | 66.32x | 66.32x |
| Quanterix Corporation (QTRX)vs › | $164.16M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.74M | N/A | N/A | N/A | N/A |
| OptimizeRx Corp. (OPRX)vs › | $166.35M | 10.47x | 86.42x | 168.75x | 173.55x |
| Codexis, Inc. (CDXS)vs › | $151.12M | N/A | 183.85x | 184.46x | 184.46x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
